Advertisement
Organisation › Details
Pfizer (Group)
At Pfizer (NYSE: PFE), we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. *
Industry | pharmaceutical | |
Region | New York, NY | |
Country | United States (USA) | |
Street | 235 East 42nd Street | |
City | 10017 New York, NY | |
Tel | +1-212-733-2323 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
Currency | USD | |
Annual sales | 48,613,000,000 (revenue, consolidated (2007) 2007-12-31) | |
Profit | 8,298,000,000 (2007-12-31) | |
* Document for »About Section«: | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Pfizer (Group)
- [1] AstraZeneca plc. (9/20/23). "Press Release: Alexion Completes Purchase and Licence Agreement for Early-stage Rare Disease Gene Therapy Portfolio from Pfizer"....
- [2] CureVac N.V.. (5/19/23). "Press Release: CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech". Tübingen....
- [3] BioNTech AG. (3/14/23). "Press Release: Pfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years". New York & Mainz....
- [4] Seagen Inc.. (3/13/23). "Press Release: Pfizer Invests $43 Billion to Battle Cancer. Pfizer to Acquire Seagen for $229 per Seagen Share in Cash". New York, NY & Bothell, WA....
- [5] BioNTech SE. (2/10/23). "Press Release: Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based Shingles Vaccine Program". New York, NY & Mainz....
- [6] Anokion S.A.. (10/18/22). "Press Release: Anokion Announces $35 Million Equity Investment from Pfizer". Cambridge, MA & Lausanne....
- [7] CytoReason Ltd.. (9/20/22). "Press Release: CytoReason Announces Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development". Tel Aviv....
- [8] Capstan Therapeutics, Inc.. (9/14/22). "Press Release: Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering". San Diego, CA & Philadelphia, PA....
- [9] BioNTech SE. (9/1/22). "Press Release: Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union". New York, NY & Mainz....
- [10] BioNTech SE. (8/31/22). "Press Release: Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older". New York, NY & Mainz....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top